YC-1 (170632-47-0) is a nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of rabbit platelets (IC50 = 14.6 μM).1 Induces human endometrial cancer cell senescence via modulation of HIF1α activity.2 Induces degradation of HIF1α.3 Protects against glutamate-induced neuronal damage4 and β-amyloid-induced toxicity in differentiated PC12 cells5.
1) Martin et al. (2001), YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components; Proc. Natl. Acad. Sci. USA, 98 12938
2) Kato et al. (2006), Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1; Int. J. Cancer, 118 1144
3) Kim et al. (2006), A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent; Int. J. Oncol., 29 255
4) Tai et al. (2018), Therapeutic window for YC-1 following glutamate-induced neuronal damage and transient focal cerebral ischemia; Mol. Med. Rep., 17 6490
5) Tsai et al. (2013), The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells.; PLoS One, 8(7) e69320